LeMaitre Vascular (LMAT) Expected to Announce Quarterly Earnings on Wednesday

LeMaitre Vascular (NASDAQ:LMAT) is expected to release its Q4 2025 results after the market closes on Wednesday, February 25th. Analysts expect the company to announce earnings of $0.67 per share and revenue of $62.9830 million for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Wednesday, February 25, 2026 at 5:00 PM ET.

LeMaitre Vascular Stock Down 1.7%

LMAT stock opened at $91.38 on Tuesday. The firm has a market cap of $2.07 billion, a price-to-earnings ratio of 39.39, a PEG ratio of 2.06 and a beta of 0.72. LeMaitre Vascular has a 1-year low of $71.42 and a 1-year high of $105.55. The firm has a fifty day moving average price of $85.71 and a two-hundred day moving average price of $88.11. The company has a debt-to-equity ratio of 0.44, a current ratio of 13.58 and a quick ratio of 11.45.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the company. Wells Fargo & Company dropped their price target on LeMaitre Vascular from $97.00 to $93.00 and set an “equal weight” rating on the stock in a research report on Friday, November 7th. Zacks Research downgraded LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research note on Thursday, January 1st. Weiss Ratings reiterated a “buy (b-)” rating on shares of LeMaitre Vascular in a research note on Monday, December 29th. Roth Mkm restated a “buy” rating and set a $108.00 price target on shares of LeMaitre Vascular in a research report on Wednesday, November 5th. Finally, Cantor Fitzgerald reiterated a “neutral” rating and issued a $95.00 price objective on shares of LeMaitre Vascular in a research report on Monday, November 10th. Four analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $100.20.

Institutional Trading of LeMaitre Vascular

Several institutional investors have recently modified their holdings of LMAT. Royal Bank of Canada grew its holdings in LeMaitre Vascular by 1.5% during the first quarter. Royal Bank of Canada now owns 114,176 shares of the medical instruments supplier’s stock worth $9,579,000 after acquiring an additional 1,735 shares during the period. AQR Capital Management LLC boosted its position in shares of LeMaitre Vascular by 36.4% during the 1st quarter. AQR Capital Management LLC now owns 27,878 shares of the medical instruments supplier’s stock valued at $2,339,000 after purchasing an additional 7,445 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of LeMaitre Vascular by 4.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,078 shares of the medical instruments supplier’s stock worth $1,013,000 after purchasing an additional 539 shares during the last quarter. Millennium Management LLC raised its holdings in shares of LeMaitre Vascular by 119.8% in the 1st quarter. Millennium Management LLC now owns 211,222 shares of the medical instruments supplier’s stock worth $17,722,000 after purchasing an additional 115,141 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its holdings in shares of LeMaitre Vascular by 27.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 262,445 shares of the medical instruments supplier’s stock worth $22,019,000 after purchasing an additional 55,804 shares in the last quarter. Institutional investors and hedge funds own 84.64% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.